Indaptus Therapeutics, Inc. (INDP) — Financial statements
Income statement, balance sheet, and cash flow for Indaptus Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 9↑28.8% | 7↓4.9% | 8↑20.5% | 6↑150.7% | 3 | |
| General & Administrative Expenses | 10↑30.9% | 8↓8.5% | 9↑2.0% | 9↑64.9% | 5 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 0.10 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 10↑29.3% | 8↓7.3% | 9↑2.0% | 9↑64.9% | 5 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 20↑29.1% | 15↓6.2% | 16↑9.8% | 15↑92.9% | 8 | |
| Total Costs & Expenses | 20↑29.1% | 15↓6.2% | 16↑9.8% | 15↑92.9% | 8 | |
| Operating Results | ||||||
| Operating Income | -20↓29.1% | -15↑6.2% | -16↓9.8% | -15↓92.9% | -8 | |
| Depreciation & Amortization | 0.00↓100.0% | 0.00↓42.8% | 0.00↓27.9% | 0.00↑26.9% | 0.00 | |
| EBITDA | -20↓29.1% | -15↑6.2% | -16↓9.8% | -15↓92.9% | -8 | |
| EBIT | -20↓29.1% | -15↑6.2% | -16↓9.8% | -15↓92.9% | -8 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00 | 0.00 | 0.00↓100.0% | 0.59↑3218.5% | 0.02 | |
| Interest Income | 0.00 | 0.00 | 0.00↓100.0% | 0.59↑3218.5% | 0.02 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | -1↓395.4% | 0.34↓64.0% | 0.96↑62.4% | 0.59↑3218.5% | 0.02 | |
| Income Before Tax | -21↓38.8% | -15↑2.6% | -15↓7.7% | -14↓85.7% | -8 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -21↓38.8% | -15↑2.6% | -15↓7.7% | -14↓85.7% | -8 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -21↓38.8% | -15↑2.6% | -15↓7.7% | -14↓85.7% | -8 | |
| Bottom-Line Net Income | -21↓38.8% | -15↑2.6% | -15↓7.7% | -14↓85.7% | -8 | |
| EPS (Basic) | -21.58↓1240.4% | -1.61↑12.5% | -1.84↓6.4% | -1.73↑8.5% | -1.89 | |
| EPS (Diluted) | -21.58↓1240.4% | -1.61↑12.5% | -1.84↓6.4% | -1.73↑8.5% | -1.89 | |
| Weighted Average Shares | 0.97↓89.7% | 9↑11.4% | 8↑1.7% | 8↑102.0% | 4 | |
| Weighted Average Diluted Shares | 0.97↓89.7% | 9↑11.4% | 8↑1.7% | 8↑102.0% | 4 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.